Cadinha & Co. LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 0.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 166,311 shares of the company’s stock after buying an additional 890 shares during the quarter. Johnson & Johnson makes up approximately 3.8% of Cadinha & Co. LLC’s investment portfolio, making the stock its 5th largest position. Cadinha & Co. LLC’s holdings in Johnson & Johnson were worth $22,001,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the business. State Street Corp grew its holdings in shares of Johnson & Johnson by 4.3% during the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after purchasing an additional 6,656,371 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in shares of Johnson & Johnson by 4.2% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 11,623,639 shares of the company’s stock worth $1,537,692,000 after purchasing an additional 473,300 shares during the period. Fisher Asset Management LLC grew its holdings in shares of Johnson & Johnson by 3.7% during the 2nd quarter. Fisher Asset Management LLC now owns 11,499,415 shares of the company’s stock worth $1,521,258,000 after purchasing an additional 405,517 shares during the period. Clearbridge Investments LLC grew its holdings in shares of Johnson & Johnson by 3.4% during the 1st quarter. Clearbridge Investments LLC now owns 9,543,827 shares of the company’s stock worth $1,188,684,000 after purchasing an additional 310,831 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Johnson & Johnson by 0.5% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,948,942 shares of the company’s stock worth $990,041,000 after purchasing an additional 42,144 shares during the period. Institutional investors own 65.61% of the company’s stock.

A number of equities analysts have recently weighed in on JNJ shares. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $148.00 price target for the company in a report on Thursday, July 27th. Credit Suisse Group reiterated a “buy” rating on shares of Johnson & Johnson in a report on Friday, August 4th. J P Morgan Chase & Co increased their price target on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a report on Wednesday, August 16th. Jefferies Group LLC set a $145.00 price target on Johnson & Johnson and gave the stock a “hold” rating in a report on Tuesday, August 15th. Finally, Cowen and Company set a $147.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a report on Thursday, August 24th. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the stock. Johnson & Johnson presently has an average rating of “Hold” and a consensus target price of $143.70.

ILLEGAL ACTIVITY NOTICE: “Cadinha & Co. LLC Has $22 Million Holdings in Johnson & Johnson (JNJ)” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.watchlistnews.com/cadinha-co-llc-has-22-million-holdings-in-johnson-johnson-jnj/1720891.html.

Shares of Johnson & Johnson (NYSE:JNJ) opened at $137.29 on Thursday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. The stock has a market capitalization of $371,653.16, a PE ratio of 19.38, a price-to-earnings-growth ratio of 2.81 and a beta of 0.82. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $144.35.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. Johnson & Johnson’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.68 EPS. equities research analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.45%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.